Table 2.
Overall prevalence of organisms in the U.S. CF Twin and Sibling Study, prevalence of infections in the U.S. CF Twin and Sibling Study in 2008 and the U.S. CF Foundation Registry[29] in 2008.
| U.S. CF Twin and Sibling Study Overall | U.S. CF Twin and Sibling Study 2008 | CF Foundation Registry 2008 | |
|---|---|---|---|
| Pa | 85.4% | 46.9% | 52.5% |
| MPa | 57.5% | Not estimated | Not estimated |
| Asp | 40.3% | Not estimated | Not estimated |
| Sa | 94.3% | 48.1% | 50.9% |
| MRSa | 39.2% | 23.6% | 22.6% |
| Bcc | 7.8% | 2.1% | 2.8% |
| Atyp | 7.3% | Not estimated | Not estimated |
| Sm | 41.6% | 11.6% | 12.5% |
| Ax | 19.6% | Not estimated | Not estimated |
| Hi | 74.2% | 15.0% | 16.3% |
| Sp | 35.8% | Not estimated | Not estimated |
| Ec | 19.4% | Not estimated | Not estimated |
| Kp | 19.8% | Not estimated | Not estimated |
Abbreviations: Pa: Pseudomonas aeruginosa MPa : mucoid Pseudomonas aeruginosa, Asp: Aspergillus fumigatus, Sa: Staphylococcus aureus, MRSa: Methicillin resistant Staphylococcus aureus, Bcc: Burkholderia cepacia complex, atyp: Atypical mycobacteria, Sm: Stenotrophomonas maltophilia, Ax: Achromobacter xylosoxidans, Hi: Haemophilus influenzae, Sp: Streptococcus pneumoniae, Ec: Escherichia coli and Kp: Klebsiella pneumoniae